SOX30 and AIDS dementia complex: In addition, we also found that SOX30 expression was correlated to clinical stage (n = 150, P = 0.036) of ADC patients, and the incidence of SOX30 over-expression was 35.29% (24/68) in clinical stage I, 29.17% (7/24) in clinical stage II and 15.79% (6/38) in clinical stage III+IV of ADC patients, respectively (Table S1).